Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

References

• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a Phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026. doi:10.1136/annrheumdis-2013-20505624595547
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–746. doi:10.1016/S0140-6736(12)60642-422748702
   PubMed Web of Science ®Google Scholar
• Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376–e383. doi:10.1111/j.1468-3083.2012.04716.x23030767
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a Phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399. doi:10.1111/bjd.1416426357944
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64(10):3156–3167. doi:10.1002/art.3462722806399
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from PALACE 1-3 polled analysis. Arthritis Res Ther. 2019;21:118. doi:10.1186/s13075-019-1901-331077258
   PubMed Web of Science ®Google Scholar
• De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi:10.2174/15733971179447462022081766
   PubMedGoogle Scholar
• Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26(9):1127–1132. doi:10.1111/j.1468-3083.2011.04230.x21923837
   PubMed Web of Science ®Google Scholar
• Zisman D, Bitterman H, Shalom G, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016;75(1):131–135. doi:10.1136/annrheumdis-2013-20514825261573
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Ayala F, Balato N. The risk of herpes zoster in patients with psoriasis: a retrospective records-based observational study. Indian J Dermatol Venereol Leprol. 2016;82(6):744. doi:10.4103/0378-6323.183630
   Web of Science ®Google Scholar
• Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431–1438. doi:10.1002/(ISSN)1529-013118050184
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–744. doi:10.1001/jama.2009.14619224750
   PubMed Web of Science ®Google Scholar
• Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229–234. doi:10.1136/annrheumdis-2011-20110822532633
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–895. doi:10.1001/jama.2013.109923462785
   PubMed Web of Science ®Google Scholar
• Adelzadeh L, Jourabchi N, Wu JJ, Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28(7):846–852. doi:10.1111/jdv.1230725081573
   PubMed Web of Science ®Google Scholar
• Marra F, Lo E, Kalashnikov V, Richardson K. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune disease: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3(4):205. doi:10.1093/ofid/ofw205
   Google Scholar
• Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151(5):533–538. doi:10.1001/jamadermatol.2014.495625797026
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50(9):1700–1711. doi:10.1093/rheumatology/ker19021690185
   PubMed Web of Science ®Google Scholar
• Frider B, Bruno A, Ponte M, Amante M. Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography. Case Rep Hepatol. 2013;2013:406901. doi:10.1155/2013/406901
   PubMedGoogle Scholar
• Lin KM, Lin JC, Tseng WY, Cheng TT. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect. 2013;46(1):65–67. doi:10.1016/j.jmii.2011.12.02022627098
   PubMedGoogle Scholar
• Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19(44):7867–7873. doi:10.3748/wjg.v19.i44.786724307780
   PubMed Web of Science ®Google Scholar
• Salvi M, Macaluso L, Luci C, et al. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases. 2016;4(2):49–55. doi:10.12998/wjcc.v4.i2.4926881191
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88–97.e5. doi:10.1016/j.jaad.2017.01.03728495497
   PubMed Web of Science ®Google Scholar
• Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009;61(3):300–304. doi:10.1002/art.2447619248128
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Angel DM, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756–761. doi:10.1002/art.2276817530674
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Research axed on tolerance of biotherapies group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884–1894. doi:10.1002/art.2463219565495
   PubMed Web of Science ®Google Scholar
• Pickens G, Moldwin E, Marder W. Healthcare spending index for employer-sponsored insurance: methodology and baseline results. Available from: http://truvenhealth.com/Portals/0/Assets/HealthInsights/TRU_15667_0415_HSI_ESI_WP.pdf. Accessed 915, 2015.
   Google Scholar
• Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol. 2014;41:2. doi:10.3899/jrheum.130658
   Web of Science ®Google Scholar
• Stoll ML, Grubbs JA, Beukelman T, et al. Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. Pediatr Rheumatol. 2017;15(1):1–6.
   Web of Science ®Google Scholar